Company: PTHS
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001753926-25-001326
Chunk: 36

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 1
Chunk 36
---
 of the Company outstanding as of the effective date of
the Reverse Stock Split.

The
new CUSIP number for the Common Stock is 171126 204.

    24 

The
Company’s transfer agent, Nevada Agency and Transfer Company, is acting as exchange agent for the Reverse Stock Split.

Departure
and Election of Directors

In
connection with the Merger and pursuant to the terms of the Merger Agreement, at the Effective Time, Francis Knuettel II, Todd
Davis, Ezra Friedberg and Chia-Lin Simmons each resigned from the Company’s board of directors (the “Board”).

In
addition, the size of the Board was increased from five to seven directors.

At
the Effective Time, one director selected by the Company, namely Dr. Richard Malamut, one director who is the newly-elected
Chief Executive Officer of the Company, namely Scott Plesha, four directors selected by LNHC, namely Peter Greenleaf, Matthew
Pauls, Todd Davis and Richard Baxter, and one member selected by Nomis Bay, namely Ezra Friedberg, were each appointed to serve
as a director of the Company until the next annual meeting of stockholders to be held after the Closing Date or until a successor
is duly elected and qualified, or until each such director’s earlier resignation or removal.

Effective
as of the Closing Date, the following committees of the Board were constituted as follows:

    ●
    Audit
    Committee: Ezra Friedberg (Chair) and Matthew Pauls.

    ●
    Compensation
    Committee: Dr. Richard Malamut and Matthew Pauls (Chair).

    ●
    Nominating
    and Corporate Governance Committee: Dr. Richard Malamut and Peter Greenleaf (Chair).

Departure
and Appointment of Certain Officers

In
connection with the Merger, on the Closing Date, Francis Knuettel’s employment as Chief Executive Officer, and President,
Treasurer and Secretary of the Company terminated. 

Additionally,
on the Closing Date, Dr. Eric Lang’s employment as Chief Medical Officer of the Company was terminated.

The
Company’s directors and the foregoing named officers have entered into customary indemnification agreements that provide
them, in general, with customary indemnification in connection with their service to the Company or on its behalf.

On
the Closing Date, the Company entered into employment agreements with Messrs. Plesha, Knuettel and Rangarao effective as
of the Closing Date